問卷

TPIDB > Search Result

Search Result

篩選

List

5Cases

2025-05-01 - 2029-03-06

Phase II

Active
A phase II, randomized, open-label, multicenter trial is being conducted to evaluate the use of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxetan in adult male patients with prostate-specific cell membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).
  • Condition/Disease

    PSMA-positive metastatic castration-resistant prostate cancer who had previously received at least one ARPI

  • Test Drug

    JSB462

Participate Sites
2Sites

Recruiting2Sites

2026-06-01 - 2030-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-02-03 - 2033-05-03

Phase II/III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-04-04 - 2029-12-07

Phase I/II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-01-26 - 2029-02-28

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites